2026-04-14T04:06:05Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/2248632026-04-07T23:28:56Zcom_2072_1057col_2072_478798col_2072_478916col_2072_478917
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Alonso Navarro, Rodrigo
Ramírez, Margarita
Masiá, Mar
Paredes, Roger
Montejano, Rocío
Povar Echeverria, Marina
Carratalà, Jordi
Salavert, Miguel
Bernal, Enrique
Dueñas, Carlos
Flores, Juan
Fanjul, Francisco
Gutiérrez, Isabel
Rico, Verónica
Mateu, Lourdes
Cadiñanos, Julen
Berenguer Berenguer, Juan
Soriano Viladomiu, Alex
Medicaments antivírics
COVID-19
Antiviral agents
COVID-19
Background
Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to remdesivir.
Methods
We conducted a retrospective multicentric study analysing all patients admitted with COVID-19 in 9 Spanish hospitals who received treatment with remdesivir in October 2020. The main outcome was the need of ICU admission after 24 h of the first dose of remdesivir.
Results
In our cohort of 497 patients, the median of days from symptom onset to remdesivir was 5 days, and 70 of them (14.1%) were later admitted into ICU. The clinical outcomes associated with ICU admission were days from symptoms onset (5 vs. 6; p = 0.023), clinical signs of severe disease (respiratory rate, neutrophil count, ferritin levels and very-high mortality rate in SEIMC-Score) and the use of corticosteroids and anti-inflammatory drugs before ICU. The only variable significatively associated with risk reduction in the Cox-regression analyses was ≤ 5 days from symptoms onset to RDV (HR: 0.54, CI95%: 0.31–0.92; p = 0.024).
Conclusion
For patients admitted to the hospital with COVID-19, the prescription of remdesivir within 5 days from symptoms onset diminishes the need of ICU admission.
2025-12-12T13:15:41Z
2025-12-12T13:15:41Z
2023-05-04
2025-12-12T13:15:41Z
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
1471-2334
https://hdl.handle.net/2445/224863
754533
37142994
eng
Reproducció del document publicat a: https://doi.org/10.1186/s12879-023-08222-y
BMC Infectious Diseases, 2023, vol. 23, num.1
https://doi.org/10.1186/s12879-023-08222-y
cc-by (c) Alonso-Navarro Rodrigo et al., 2023
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
7 p.
application/pdf
BioMed Central
Articles publicats en revistes (Ciències Clíniques)